Effectiveness, safety and quality-of-life effects of guselkumab and ustekinumab in patients with psoriasis: Week 104 results from the non-interventional, prospective, German multicentre PERSIST study.
Sascha GerdesM HoffmannK AsadullahB KorgeD MortazawiN KrügerY PersonkeS TaboriM GomezS WegnerF KreimendahlF TautM SticherlingPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Ustekinumab and guselkumab led to improvements in physician-assessed and patient-reported outcomes that were sustained for up to 2 years, with no new safety signals identified. Following propensity score matching, greater improvements in PASI outcomes were observed with guselkumab versus ustekinumab. Improvements with guselkumab were highest in biologic-naïve patients, highlighting the value of early treatment.
Keyphrases
- patient reported outcomes
- end stage renal disease
- chronic kidney disease
- ejection fraction
- systematic review
- emergency department
- newly diagnosed
- randomized controlled trial
- primary care
- clinical trial
- rheumatoid arthritis
- prognostic factors
- cross sectional
- type diabetes
- metabolic syndrome
- combination therapy
- skeletal muscle
- replacement therapy
- insulin resistance